GleamWall
中文EN

ACOG Alpha Cognition Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1655923 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-48.6%
TTM EPS YoY8.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin99.8%
Operating margin-149.6%
Net margin-147.3%
FCF margin-152.7%
EBITDA margin-148.2%

Returns

ROE-74.2%
ROA-53.9%
ROIC (approx.)-696.4%
Asset turnover0.37x

Leverage & solvency

Liabilities / assets22.9%
Debt / equity0.00x
Current ratio7.13x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.02x
Accruals ratio1.2%
Payout ratio—
Capex / revenue2.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$7.78M$6.09M$3.53M$2.79M$2.84M$1.66M$2.93M—
Cost of revenue$482,421$391,057$248,853-$1.08M$633,448$203,858$26,541—
Gross profit$7.29M$5.70M$3.28M$3.87M$2.21M$1.45M$2.90M—
R&D expense$1.34M$2.01M$1.10M$569,749$513,783$406,140$400,416$1.04M
SG&A expense$12.38M$11.45M$10.26M$9.89M$5.11M$9.49M$5.09M$1.63M
Operating income-$6.43M-$7.76M-$8.10M-$7.93M-$3.42M-$8.45M-$3.40M-$2.54M
Interest expense—————-$644$8,807$63,120
Net income-$7.62M-$8.79M-$6.48M-$6.86M$574,380-$13.20M-$1.73M-$5.66M
EBITDA-$6.31M-$7.65M-$8.07M-$7.90M-$3.41M-$8.44M-$3.40M-$2.52M
EPS (basic)-0.35-0.40-0.30—0.04-0.82-0.11—
EPS (diluted)-0.35-0.40-0.32—-0.29-0.82-0.11—
Weighted avg. shares (diluted)21.86M21.77M21.93M—16.83M16.02M16.02M—
Banking
Provision for credit losses———————$0
Balance sheet
Cash & equivalents$37.80M$41.38M$54.25M$66.05M$35.46M$39.46M$45.62M$48.56M
Receivables$6.98M$5.47M$3.58M$4.24M$2.85M$1.81M$422,796—
Inventory$6.41M$6.39M$6.04M$5.12M$4.50M$875,852$883,376$615,133
Current assets$57.35M$57.93M$68.56M$79.01M$45.70M$44.65M$48.12M$50.25M
PP&E, net$524,255$374,692$305,479$328,540$202,754$72,539$70,452$27,077
Intangibles$6.13M$6.22M$386,036$391,423$396,809$402,196$407,582$412,969
Total assets$64.00M$64.52M$69.25M$79.73M$46.30M$45.12M$48.61M$50.74M
Current liabilities$8.04M$6.41M$5.43M$9.13M$6.83M$3.04M$2.81M$3.35M
Total liabilities$14.68M$11.56M$11.79M$17.20M$12.39M$13.23M$7.80M$11.64M
Shareholders' equity$49.32M$54.04M$57.46M$62.53M$30.79M$26.72M$38.50M$39.09M
Shares outstanding21.99M21.77M21.77M21.74M16.25M16.02M16.02M16.02M
Cash flow statement
Operating cash flow-$4.85M-$6.86M-$11.80M-$6.91M-$5.29M-$6.14M-$2.04M-$2.30M
Capital expenditure$182,094$98,570$1,322$147,523$74,381$8,315$63,270—
Free cash flow-$5.03M-$6.96M-$11.80M-$7.05M-$5.36M-$6.15M-$2.11M—
Investing cash flow-$182,094-$6.01M-$1,322-$147,523-$74,381-$8,315-$63,270—
Financing cash flow$1.45M$0$800$37.70M$1.36M-$10,808-$834,303$47.12M
Depreciation & amortization$120,529$103,586$29,770$27,123$12,553$11,614$7,282$20,395
Stock-based compensation$1.45M$1.45M$1.40M$945,502$897,581$1.39M$1.13M$62,646

Free plan shows the latest 8 periods; Pro shows all 14 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.